Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with plans to file two lawsuits and send about 50 cease-and-desist letters, Bloomberg’s Nyah Phengsitthy reports. The company is demanding that the compounders and telehealth companies stop mass producing tirzepatide, a diabetes and obesity treatment branded as Mounjaro and Zepbound. Novo Nordisk (NVO) markets Ozempic and Wegovy injections, while Hims & Hers (HIMS) is a compounder of the weight loss drug whose shares are often volatile around news regarding GLP-1 drugs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Pharmaceutical Industry Leaders Want to Delay Trump Tariffs
- Roku, Tesla among Q2 Tactical Ideas at Wells Fargo
- Pharmaceutical Stocks Dive as Top FDA Vaccine Regulator Departs
- Eli Lilly announces Phase 2 trial of lepodisiran met primary endpoint
- Eli Lilly’s (LLY) Alzheimer’s Drug Is Rejected in Europe Over Safety Fears